AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20691834 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg/d)
Number of subjects: 1229
Study 20691834 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1229
Study 19026871 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL of 1% diphenhydramine with 1:100,000 epinephrine
Number of subjects: 0
Study 19026871 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 0
Study 19026871 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mL of 2% lidocaine with 1:100,000 epinephrine combined with 1% diphenhydramine with 1:100,000 epinephrine
Number of subjects: 0
Study 15781499 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA) with fentanyl (7-15 microg/kg) and morphine infusion
Number of subjects: 120
Study 15781499 — intervention group
Group type: EXPERIMENTAL
Intervention: High Thoracic Epidural Anesthesia (HTEA) with fentanyl (5-7 microg/kg) and epidural infusion of ropivacaine 0.2% and fentanyl 2 microg/mL until postoperative Day 3
Number of subjects: 120
Study 15781499 — intervention group
Group type: EXPERIMENTAL
Intervention: High Thoracic Epidural Anesthesia (HTEA)
Number of subjects: 120
Study 12519833 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg/d orally)
Number of subjects: 38
Study 12519833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 11508548 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (500 microg/d)
Number of subjects: 27
Study 8645639 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine midtrimester ultrasound examination
Number of subjects: 0
Study 8645639 — intervention group
Group type: COMPARATOR
Intervention: Selective obstetric ultrasonography
Number of subjects: 0
Study 1346410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (5 mg/kg per day for 12 weeks)
Number of subjects: 33
Study 31983187 — intervention group
Group type: EXPERIMENTAL
Intervention: B-CAM-M (Malay version of Breast Cancer Awareness Measure)
Number of subjects: 251
Study 31983187 — intervention group
Group type: EXPERIMENTAL
Intervention: B-CAM-M
Number of subjects: 251
Study 31167001 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal stimulation at different temperatures (including 44°C)
Number of subjects: 0
Study 31167001 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal stimulation at 44°C
Number of subjects: 0
Study 31167001 — intervention group
Group type: COMPARATOR
Intervention: Same thermal stimulation
Number of subjects: 0
Study 29960287 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinbei Qingfei Yiqi (QBQFYQ) granules plus usual treatment
Number of subjects: 80
Study 29960287 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 80
Study 26457385 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted behavioral group intervention
Number of subjects: 178
Study 26457385 — intervention group
Group type: COMPARATOR
Intervention: Supportive group intervention
Number of subjects: 178
Study 23756075 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (C‐A‐T)
Number of subjects: 0
Study 23756075 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Operations Forces Tactical Tourniquet Wide
Number of subjects: 0
Study 23756075 — intervention group
Group type: COMPARATOR
Intervention: Other tourniquet types
Number of subjects: 0
Study 22259899 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia combined with nerve stimulator guided bilateral paravertebral block
Number of subjects: 60
Study 22259899 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia combined with normal saline nerve stimulator guided bilateral paravertebral block
Number of subjects: 60
Study 19303966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose supplemental vitamins E plus C
Number of subjects: 4
Study 19303966 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose supplemental vitamins E plus C
Number of subjects: 4
Study 19303966 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose supplemental vitamins E plus C
Number of subjects: 4
Study 19303966 — intervention group
Group type: COMPARATOR
Intervention: No vitamins
Number of subjects: 4
Study 17535222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing programme 'Coping with Itch' (mean of 2.9 visits)
Number of subjects: 65
Study 17535222 — intervention group
Group type: COMPARATOR
Intervention: Usual care from a dermatologist (control group)
Number of subjects: 65
Study 15156934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry supplement (400 mg, 3 times a day for 4 weeks)
Number of subjects: 21
Study 15156934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11493247 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate group (n = 20)
Number of subjects: 40
Study 11493247 — intervention group
Group type: COMPARATOR
Intervention: Saline group (n = 20)
Number of subjects: 40
Study 9929676 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory problem
Number of subjects: 80000
Study 9929676 — intervention group
Group type: EXPERIMENTAL
Intervention: Gustatory problem
Number of subjects: 80000
Study 9929676 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemosensory problem (combined smell and taste)
Number of subjects: 80000
Study 9929676 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 65 years or greater with chemosensory problem
Number of subjects: 80000
Study 9929676 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related characteristics
Number of subjects: 80000
Study 8057219 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate formula (CHF)
Number of subjects: 130
Study 8057219 — intervention group
Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 130
Study 8057219 — intervention group
Group type: COMPARATOR
Intervention: Cow-milk formula (CMF)
Number of subjects: 130
Study 3377928 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 5 mg
Number of subjects: 8
Study 3377928 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 8
Study 31916919 — intervention group
Group type: EXPERIMENTAL
Intervention: KORSA workshops (4-week intervention)
Number of subjects: 124
Study 31916919 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 124
Study 30554216 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid diet (n = 50)
Number of subjects: 100
Study 30554216 — intervention group
Group type: COMPARATOR
Intervention: Liquid diet (n = 50)
Number of subjects: 100
Study 27817037 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight (<18.5 kg/m2)
Number of subjects: 800
Study 27817037 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight (19‐23.9 kg/m2)
Number of subjects: 800
Study 27817037 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (24‐27.9 kg/m2)
Number of subjects: 800
Study 27817037 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese (≥28 kg/m2)
Number of subjects: 800
Study 27817037 — intervention group
Group type: EXPERIMENTAL
Intervention: Total recombinant follicle‐stimulating hormone (rFSH) dose
Number of subjects: 800
Study 27817037 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pregnancy rate per transfer
Number of subjects: 800
Study 27817037 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical pregnancy rate
Number of subjects: 800
Study 27817037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing pregnancy rate
Number of subjects: 800
Study 27817037 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscarriage rate
Number of subjects: 800
Study 25951232 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus nab-paclitaxel
Number of subjects: 0
Study 25951232 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 0
Study 24053627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid administered 24 hours after endoscopic procedure for 14 days
Number of subjects: 2
Study 24053627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 2
Study 20963602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided reduction
Number of subjects: 68
Study 20963602 — intervention group
Group type: COMPARATOR
Intervention: Simple closed reduction
Number of subjects: 68
Study 19820872 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estriol therapy for 14 days
Number of subjects: 27
Study 19820872 — intervention group
Group type: COMPARATOR
Intervention: Control group (no estriol therapy)
Number of subjects: 27
Study 17364516 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized working memory training for five weeks
Number of subjects: 18
Study 14751328 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention with photo book (Group A, n=49)
Number of subjects: 100
Study 14751328 — intervention group
Group type: COMPARATOR
Intervention: Teaching intervention only (Group B, n=51)
Number of subjects: 100
Study 14751328 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 100
Study 11887979 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictions made by clinicians (internist, surgeon, general practitioner)
Number of subjects: 402
Study 9227927 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b combined with cytarabine (20 mg per square meter per day for 10 days, plus hydroxyurea 50 mg per kilogram per day)
Number of subjects: 721
Study 9227927 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2b alone (plus hydroxyurea 50 mg per kilogram per day)
Number of subjects: 721
Study 9227927 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b combined with cytarabine
Number of subjects: 721
Study 9227927 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone
Number of subjects: 721
Study 7954535 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide, 25 mg/day
Number of subjects: 12
Study 7954535 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide, 10 mg/day
Number of subjects: 12
Study 3664553 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 179
Study 3664553 — intervention group
Group type: COMPARATOR
Intervention: Aspirin with codeine
Number of subjects: 179
Study 31957269 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness relaxation (MR)
Number of subjects: 474
Study 31957269 — intervention group
Group type: COMPARATOR
Intervention: Relaxing music (RM)
Number of subjects: 474
Study 31957269 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care (SC)
Number of subjects: 474
Study 30908421 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils fiberscope
Number of subjects: 15
Study 30908421 — intervention group
Group type: COMPARATOR
Intervention: SensaScope fiberscope
Number of subjects: 15
Study 28058750 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg
Number of subjects: 222
Study 28058750 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 222
Study 28058750 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg after 52 weeks
Number of subjects: 222
Study 28058750 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg after 52 weeks
Number of subjects: 222
Study 26232505 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactooligosaccharide (1.7 g)
Number of subjects: 20
Study 26232505 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 20
Study 23394340 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin for 7 days after tumor resection (prophylaxis group)
Number of subjects: 123
Study 23394340 — intervention group
Group type: COMPARATOR
Intervention: No seizure prophylaxis (observation group)
Number of subjects: 123
Study 21360125 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous conditioned serum (ACS)
Number of subjects: 62
Study 21360125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 19159475 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable heroin maintenance
Number of subjects: 0
Study 19159475 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 0
Study 17876014 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (Erl) 150 mg daily combined with Bevacizumab (Bev) 10 mg/kg every 2 weeks
Number of subjects: 104
Study 17876014 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (Bev) 10 mg/kg every 2 weeks
Number of subjects: 104
Study 17876014 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (Erl) combined with Bevacizumab (Bev)
Number of subjects: 104
Study 17876014 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (Bev) alone
Number of subjects: 104
Study 16420077 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (4 mg/day initiated, flexibly dosed to a maximum of 16 mg/day)
Number of subjects: 266
Study 16420077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 16420077 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 266
Study 12447511 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 49
Study 12447511 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (ETI)
Number of subjects: 49
Study 9593991 — intervention group
Group type: EXPERIMENTAL
Intervention: Landmark information
Number of subjects: 0
Study 9593991 — intervention group
Group type: EXPERIMENTAL
Intervention: Landmark and geometric information
Number of subjects: 0
Study 10155183 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodiafiltration
Number of subjects: 100
Study 2146038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator (Alteplase or Duteplase)
Number of subjects: 18
Study 2146038 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (Anistreplase)
Number of subjects: 18
Study 344156 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran (high-fibre diet)
Number of subjects: 22
Study 31789445 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 7020
Study 31789445 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 7020
Study 31789445 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study 29893592 — intervention group
Group type: EXPERIMENTAL
Intervention: D-aspartic acid (DAA) 3 g/day for 2 weeks
Number of subjects: 16
Study 29893592 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 g/day for 2 weeks
Number of subjects: 16
Study 28328065 — intervention group
Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS+50%FERM
Number of subjects: 432
Study 28328065 — intervention group
Group type: COMPARATOR
Intervention: scGOS/lcFOS
Number of subjects: 432
Study 28328065 — intervention group
Group type: COMPARATOR
Intervention: 50%FERM
Number of subjects: 432
Study 25981371 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided therapy
Number of subjects: 0
Study 25981371 — intervention group
Group type: COMPARATOR
Intervention: Symptom-guided therapy
Number of subjects: 0
Study 25008012 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-like diet high in protein
Number of subjects: 0
Study 25008012 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-like diet high in unsaturated fats
Number of subjects: 0
Study 25008012 — intervention group
Group type: COMPARATOR
Intervention: DASH-like diet high in carbohydrates
Number of subjects: 0
Study 21478659 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated protocol (n=13)
Number of subjects: 29
Study 21478659 — intervention group
Group type: COMPARATOR
Intervention: Slow protocol (n=16)
Number of subjects: 29
Study 18992951 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS Type 1 (single exponential)
Number of subjects: 270
Study 18992951 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS Type 2 (non-exponential)
Number of subjects: 270
Study 16520409 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone (500 microg)
Number of subjects: 13
Study 16520409 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone with L‐NMMA
Number of subjects: 13
Study 16520409 — intervention group
Group type: COMPARATOR
Intervention: L‐NMMA alone
Number of subjects: 13
Study 15531664 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 3 g beta-glucan/d from barley
Number of subjects: 25
Study 15531664 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 6 g beta-glucan/d from barley
Number of subjects: 25
Study 15531664 — intervention group
Group type: COMPARATOR
Intervention: Control diet with no beta-glucan
Number of subjects: 25
Study 15531664 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grains incorporated into the diets
Number of subjects: 25
Study 15531664 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 25
Study 11050610 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical care
Number of subjects: 20
Study 11050610 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 20
Study 11050610 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injections
Number of subjects: 20
Study 11050610 — intervention group
Group type: COMPARATOR
Intervention: Self-care advice (minimal intervention control group)
Number of subjects: 20
Study 9282055 — intervention group
Group type: EXPERIMENTAL
Intervention: K Care
Number of subjects: 20
Study 8442804 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cesarean section
Number of subjects: 38
Study 8442804 — intervention group
Group type: COMPARATOR
Intervention: Observed labor
Number of subjects: 38
Study 3107442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (0.1 mg X kg‐1)
Number of subjects: 6
Study 3107442 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg X kg‐1)
Number of subjects: 6
Study 3107442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 28817248 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 14
Study 28817248 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 14
Study 27451354 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Compassionate Living (MBCL) in addition to treatment as usual (TAU)
Number of subjects: 0
Study 27451354 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 27451354 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Compassionate Living (MBCL)
Number of subjects: 0
Study 24942553 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (EPA:DHA = 0.9:1.5; 9 μM EPA plus 15 μM DHA)
Number of subjects: 20
Study 24350814 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (n=9)
Number of subjects: 30
Study 24350814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (n=10)
Number of subjects: 30
Study 24350814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 30
Study 20837788 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vision device training (additional appointment for device handling)
Number of subjects: 96
Study 20837788 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard low vision assessment without additional training)
Number of subjects: 96
Study 19463342 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 0
Study 19463342 — intervention group
Group type: COMPARATOR
Intervention: Vascular brachytherapy (VBT)
Number of subjects: 0
Study 16509177 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen concentrator
Number of subjects: 10
Study 16509177 — intervention group
Group type: COMPARATOR
Intervention: Piped oxygen
Number of subjects: 10
Study 14499226 — intervention group
Group type: EXPERIMENTAL
Intervention: Countries with the highest tertile of in-hospital revascularization rates (>39%)
Number of subjects: 16949
Study 14499226 — intervention group
Group type: COMPARATOR
Intervention: Countries with intermediate tertile of in-hospital revascularization rates (15-39%)
Number of subjects: 16949
Study 14499226 — intervention group
Group type: COMPARATOR
Intervention: Countries with the lowest tertile of in-hospital revascularization rates (<15%)
Number of subjects: 16949
Study 11137414 — intervention group
Group type: EXPERIMENTAL
Intervention: IV diclofenac (0.7 mg/kg bolus followed by 0.15 mg/kg/hr infusion)
Number of subjects: 40
Study 11137414 — intervention group
Group type: COMPARATOR
Intervention: Saline (equal volume to diclofenac)
Number of subjects: 40
Study 9171947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FX) 40 mg
Number of subjects: 0
Study 9171947 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (Nal)
Number of subjects: 0
Study 8268117 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1.6% alone
Number of subjects: 34
Study 8268117 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.6% with 1% meperidine
Number of subjects: 34
Study 2445326 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton laser photocoagulation
Number of subjects: 288
Study 2445326 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 288
Study 30038154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of retinal length to choroidal length ratio (RCR) before training
Number of subjects: 50
Study 30038154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of retinal length to choroidal length ratio (RCR) after training
Number of subjects: 50
Study 30038154 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between RCR and interobserver difference
Number of subjects: 50
Study 26718419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal capsaicin infusion (1.5 mg pure capsaicin)
Number of subjects: 13
Study 25342282 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine
Number of subjects: 102
Study 23184657 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid GAD/MDD group
Number of subjects: 1218
Study 23184657 — intervention group
Group type: COMPARATOR
Intervention: MDD group
Number of subjects: 1218
Study 23184657 — intervention group
Group type: COMPARATOR
Intervention: GAD group
Number of subjects: 1218